Evidence map›Paper›PMID 36466676›Full record

ReviewFrontiers in microbiology2022

Nanomaterials-based vaccines to target intracellular bacterial pathogens.

Megan A Files, Kadin M Kristjansson, Jai S Rudra, Janice J Endsley

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Megan A FilesDepartment of Microbiology and Immunology, Galveston, TX, United States.
Kadin M KristjanssonDepartment of Chemistry, Smith College, Northampton MA, United States.
Jai S RudraDepartment of Biomedical Engineering, McKelvey School of Engineering, Washington University in St. Louis, St. Louis, MO, United States.
Janice J EndsleyDepartment of Microbiology and Immunology, Galveston, TX, United States.
Washington University in St. Louis · USGalveston College · USThe University of Texas Medical Branch at Galveston · US

Funding

Self-assembling Peptide Nanomaterials for Eliciting Mucosal CD8+ T cell ImmunityR21AI115302 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ENDSLEY, JANICE J, RUDRA, JAI · 2016 to 2017
$416k
NIAID NIH HHS R21 AI115302
6 · The paper itself

Abstract

Development of novel immunization approaches to combat a growing list of emerging and ancient infectious agents is a global health priority. Intensive efforts over the last several decades have identified alternative approaches to improve upon traditional vaccines that are based on live, attenuated agents, or formulations of inactivated agents with adjuvants. Rapid advances in RNA-based and other delivery systems for immunization have recently revolutionized the potential to protect populations from viral pathogens, such as SARS-CoV-2. Similar efforts to combat bacterial pathogens, especially species with an intracellular niche, have lagged significantly. In the past decade, advances in nanotechnology have yielded a variety of new antigen/adjuvant carrier systems for use in vaccine development against infectious viruses and bacteria. The tunable properties of nanomaterial-based vaccines allow for balancing immunogenicity and safety which is a key hurdle in traditional antigen and adjuvant formulations. In this review, we discuss several novel nanoparticle-based vaccine platforms that show promise for use against intracellular bacteria as demonstrated by the feasibility of construction, enhanced antigen presentation, induction of cell mediated and humoral immune responses, and improved survival outcomes in

Indexed as

intracellular bacterial pathogensMycobacterium tuberculosisnanomaterialspeptide nanofibersvaccines

Identifiers

PMID36466676
PMCPMC9715960
OpenAlexW4309462889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.